Stablepharma, a British pharmaceutical company, has successfully tested vaccines that do not require refrigeration in patients for the first time.
The breakthrough uses trehalose, a sugar that converts vaccines into powder stable at room temperature.
Since roughly half of all vaccines are wasted annually due to temperature damage during transport and storage—a challenge especially acute in Africa—this innovation could significantly improve immunization rates in regions with limited electricity infrastructure.
What happened
British pharmaceutical company Stablepharma has successfully trialed vaccines that require no refrigeration for the first time in patients. The technology uses a sugar called trehalose to turn vaccines into powder that can be stored at room temperature and mixed with water before injection. A larger trial is due to begin in the coming months.
Why it matters
Around half of all vaccines are wasted each year because they become unusable when exposed to temperature swings during production, transport, and delivery—a problem called "cold chain" breakdown. Removing the refrigeration requirement could unlock immunization access in regions where reliable electricity is scarce. One in five children in Africa remains unvaccinated, according to the World Health Organization.
What to watch
The larger trial beginning in the coming months is described as the final research hurdle before potential rollout. Success would clear the path for deployment in settings where maintaining cold storage has been a major barrier to vaccine coverage.
Vaccines that do not require refrigeration have been successfully trialed in patients for the first time, a development that could reshape immunization access across Africa and other low-income regions. The technology was developed by British pharmaceutical company Stablepharma and works by using a sugar called trehalose to convert vaccines into a powder form. This powder can be stored safely at room temperature, eliminating the need for refrigeration, and is later reconstituted with water at the point of injection. The innovation directly targets a major driver of global vaccine waste: the "cold chain" problem. Current vaccines, including the tetanus-diphtheria jab used in the trial, must be refrigerated or frozen throughout production, transport, and storage. When temperatures fluctuate—as they frequently do in regions with limited infrastructure—the vaccines become unusable. The result is staggering: around half of all vaccines are wasted each year. In Africa, this barrier contributes directly to vaccination gaps; one in five children on the continent remain unvaccinated, according to the World Health Organization. A larger trial is scheduled to begin in the coming months, which the article describes as the final research hurdle before potential rollout. If successful, this trial will likely clear the way for deployment in settings where reliable electricity and cold storage infrastructure have historically been insurmountable obstacles to immunization programs.
Vaccine waste has long been a critical barrier to immunization in low-income regions, particularly Africa. The article identifies that around half of all vaccines are wasted annually, with much of that loss stemming from breaks in the "cold chain"—the requirement to maintain precise temperatures from manufacturing through patient injection. In Africa specifically, one in five children remain unvaccinated, a gap that reflects not just access to vaccines themselves but the infrastructure cost of maintaining cold storage across supply chains that span vast distances with limited electricity. Stablepharma's trehalose-powder approach directly addresses this bottleneck by eliminating the need for refrigeration altogether, moving the temperature-stability problem from logistics to chemistry. The successful first-in-patient trial is significant because it proves the concept works in real conditions, not merely in the laboratory. The coming larger trial represents the final regulatory and safety validation step before potential rollout, suggesting the path to deployment is now concrete rather than theoretical.
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytime
Ask AI anything about this article. Q&As are published on this page for other readers too.
The AI news that matters, in one minute each morning.
Sign up free